172 related articles for article (PubMed ID: 2929586)
1. Long-term effect of splenectomy on transfusion requirements in thalassemia major.
Cohen A; Gayer R; Mizanin J
Am J Hematol; 1989 Apr; 30(4):254-6. PubMed ID: 2929586
[TBL] [Abstract][Full Text] [Related]
2. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
Silvestroni E; Bianco I; Graziani B; Lerone M; Valente M; Congedo P; Ponzini D; Costantini S
Acta Haematol; 1982; 68(2):115-23. PubMed ID: 6812366
[TBL] [Abstract][Full Text] [Related]
3. Chelation therapy in beta-thalassemia major. III. The role of splenectomy in achieving iron balance.
Graziano JH; Piomelli S; Hilgartner M; Giardina P; Karpatkin M; Andrew M; LoIacono N; Seaman C
J Pediatr; 1981 Nov; 99(5):695-9. PubMed ID: 7299540
[TBL] [Abstract][Full Text] [Related]
4. Clinical management of beta-thalassemia.
Graziano J; Piomelli S
Tex Rep Biol Med; 1980-1981; 40():355-64. PubMed ID: 7034276
[No Abstract] [Full Text] [Related]
5. Splenectomy for children with thalassemia.
Al-Salem AH; Nasserulla Z
Int Surg; 2002; 87(4):269-73. PubMed ID: 12575813
[TBL] [Abstract][Full Text] [Related]
6. Medical management of beta-thalassemia.
Lerner N
Prog Clin Biol Res; 1989; 309():13-22. PubMed ID: 2780747
[No Abstract] [Full Text] [Related]
7. [Chelating therapy in beta-thalassemia].
Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
[TBL] [Abstract][Full Text] [Related]
8. Transfusion requirements and splenectomy in thalassemia major.
Cohen A; Markenson AL; Schwartz E
J Pediatr; 1980 Jul; 97(1):100-2. PubMed ID: 7381628
[No Abstract] [Full Text] [Related]
9. The management of the improved prognosis in thalassemia major.
Modell B
Birth Defects Orig Artic Ser; 1982; 18(7):329-37. PubMed ID: 6819016
[No Abstract] [Full Text] [Related]
10. Treatment of iron overload in Cooley's anemia.
Cohen A; Mizanin J; Schwartz E
Ann N Y Acad Sci; 1985; 445():274-81. PubMed ID: 3860130
[No Abstract] [Full Text] [Related]
11. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
Borgna-Pignatti C; Rugolotto S; De Stefano P; Zhao H; Cappellini MD; Del Vecchio GC; Romeo MA; Forni GL; Gamberini MR; Ghilardi R; Piga A; Cnaan A
Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202
[TBL] [Abstract][Full Text] [Related]
12. High-dose intravenous chelation therapy with deferoxamine.
Cohen A; Mizanin J; Schwartz E
Prog Clin Biol Res; 1989; 309():125-31. PubMed ID: 2780746
[No Abstract] [Full Text] [Related]
13. Partial splenectomy in homozygous beta thalassaemia.
de Montalembert M; Girot R; Revillon Y; Jan D; Adjrad L; Ardjoun FZ; Belhani M; Najean Y
Arch Dis Child; 1990 Mar; 65(3):304-7. PubMed ID: 2334210
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation by scintigraphy and blood requirements of secondary hypersplenism after splenectomy in homozygous beta-thalassemia].
Esposito L; Ferrara M; Ponte G; Cioffi L; Squame G; Celentano L
Pediatria (Napoli); 1983; 91(1):13-8. PubMed ID: 6889086
[No Abstract] [Full Text] [Related]
15. [Serum ferritin in the follow-up of homozygotic beta-thalassemia treated with blood transfusion and iron-chelating agents].
Esposito L; Ferrara M; Ponte G
Pediatria (Napoli); 1981 Sep; 89(3):479-92. PubMed ID: 7346759
[No Abstract] [Full Text] [Related]
16. Bone metabolism in thalassemia.
Garofalo F; Piga A; Lala R; Chiabotto S; Di Stefano M; Isaia GC
Ann N Y Acad Sci; 1998 Jun; 850():475-8. PubMed ID: 9668589
[No Abstract] [Full Text] [Related]
17. [Thalassemia major: chelating therapy with deferoxamine].
Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
[No Abstract] [Full Text] [Related]
18. [Monitoring and appraisal of the effects of blood transfusion and iron chelation in thalassemia major].
Girot R; Triadou P; Bories D; Jeannel F; Thevenin M; Rymer JC
Nouv Rev Fr Hematol (1978); 1982; 24(5):281-7. PubMed ID: 7167380
[TBL] [Abstract][Full Text] [Related]
19. [Our experience with "supertransfusive" treatment of homozygous beta-thalassemia].
Esposito L; Ferrara M; Ponte G
Pediatria (Napoli); 1983; 91(1):27-30. PubMed ID: 6889088
[No Abstract] [Full Text] [Related]
20. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
